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Vitamin D-status i en norsk befolkning: assosiert med lungefunksjon? 
 Vitamin D syntetiseres i huden ved direkte UVB-eksponering fra solen. 
Vitamin D kan også tilføres kroppen ved inntak av vitamin-D-rik mat, eller ved bruk av 
kosttilskudd som inneholder vitamin D. Lav vitamin-D-status har blitt rapportert på 
verdensbasis, og kjente risikofaktorer inkluderer ueksponert hud, høye breddegrader, 
vintersesong og høy kroppsmasseindeks (BMI). Serum 25-hydroxyvitamin D 
(25(OH)D) er den viktigste sirkulerende metabolitt av vitamin D og regnes som den 
beste markøren for vitamin D-status. Sammenhengen mellom vitamin D-status og 
beinhelse er godt dokumentert, og økende bevis tyder på en sammenheng mellom lavt 
serum 25(OH)D nivå og et spekter av tilstander som ikke er knyttet til skjelettet, 
inkludert luftveislidelser som astma. 
 Denne avhandlingen bruker data fra Helseundersøkelsene i Nord-Trøndelag, 
en av de største befolkningsbaserte helseundersøkelsene i Norge, hvor klinisk-, livsstils- 
og miljøinformasjon for flere enn 130,000 mennesker har blitt samlet inn over en 25 års 
periode. Ved hjelp av data fra HUNT2 (1995-1997) og HUNT3 (2006-2008), 
undersøkte vi: 1) forekomsten av vitamin-D-mangel (serum 25(OH)D<50nmol/L) i en 
generell voksen befolkning og faktorer forbundet med vitamin-D-mangel; 2) 
sammenhengen mellom serum 25(OH)D nivå og lungefunksjon (LF) hos voksne med 
astma; og 3) sammenhengen mellom serum 25(OH)D nivå, røyking og LF endringer i 
en generell voksen befolkning. 
 Vi fant høy forekomst av vitamin-D-mangel i denne norske befolkning (40% 
totalt), spesielt i vintermånedene (64 %). Foruten om sesong og høy BMI, ble flere 
potensielt påvirkningsmulige livsstilsfaktorer forbundet med vitamin-D-mangel. Vi fant 
også at lavt serum 25(OH)D nivå ikke var assosiert med luftveisobstruksjon hos de 
 
 
fleste voksne med astma, med unntak av menn med astma, men uten allergi. Vi fant t 
ingen klare assosiasjoner mellom serum 25 (OH) D-nivåer og lungefunksjonsendringer 
hos ikke-røykere, mens vi derimot observerte betydningsfulle sammenhenger hos 
røykere. 
 Ytterligere forskning er nødvendig for å avgjøre om vitamin-D-tilskudd kan 
være en kostnadseffektiv, sikker og enkel måte å kontrollere astmaplager på eller for å 
lindre symptomer hos røykere.  
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Summary 
Vitamin D is predominantly synthesized from precursors in the skin after direct 
exposure to ultraviolet B radiation from the sun. Vitamin D can also be obtained by 
dietary intake of vitamin D rich food, or by supplement intake. Poor vitamin D status 
has been reported worldwide. Determinants include unexposed skin, high latitude, 
winter season, and high body mass index (BMI). Serum 25-hydroxyvitamin D 
(25(OH)D) is the major circulating metabolite of vitamin D and considered the best 
marker of vitamin D status. The association between vitamin D status and bone health is 
well studied, and increasing evidence suggests an association between low serum 
25(OH)D level and range of non-skeletal health outcomes including respiratory 
disorders, such as asthma.  
This dissertation uses data from the Nord-Trøndelag Health Study (HUNT), one 
of the largest population based health studies in Norway, with clinical, lifestyle and 
environmental information on more than 130,000 people collected over 25 years. Using 
data from HUNT2 (1995-1997) and HUNT3 (2006-2008), we investigated: 1) the 
prevalence of vitamin D deficiency (serum 25(OH)D<50nmol/L) in a general adult 
population and factors associated with vitamin D deficiency; 2) the association between 
serum 25(OH)D level and lung function (LF) in adults with asthma; and 3) the 
interrelationship between serum 25(OH)D level, smoking and LF changes in a general 
adult population.  
We found a high prevalence of vitamin D deficiency in this Norwegian 
population (40% overall), particularly in winter months (64%). Besides season and high 
BMI, several potentially modifiable lifestyle factors were associated with vitamin D 
 
 
deficiency. We also found that low serum 25(OH)D level was not associated with 
airway obstruction in most adults with asthma, with the exception of men with asthma 
but without allergy status. Finally, we found no clear associations between serum 
25(OH)D levels and LF changes in never smokers, whereas we did observe significant 
associations in ever smokers.  
Replication and confirmation of these findings via well-designed prospective 
and intervention studies is required to determine if vitamin D supplementation is a 
potentially cost effective, safe and straightforward means of asthma control or disease 
mitigation in ever smokers. 
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1 Introduction 
1.1 Vitamin D status and serum 25-hydroxyvitamin D  
Vitamin D is predominantly synthesized from precursors in the skin after direct 
exposure to ultraviolet B (UV-B) radiation from the sun[1]. UVB radiation from the sun 
activates 7-dehydrocholesterol (7-DHC) in the epidermal and dermal layers of the skin 
to form previtamin D3 which is then transformed to vitamin D3 (VD3) via thermally 
induced isomerization[2]. To a lesser extent, vitamin D can also be obtained by dietary 
intake from plants (ergocalciferol, vitamin D2 (VD2)) or oily fish (cholecalciferol, 
VD3)[3]. Whether activated in the skin after UVB exposure from the sun, or obtained 
from food or supplements, VD is transported by the vitamin-D binding protein to the 
liver where it is hydroxylated to form 25-hydroxyvitamin D (25(OH)D). Serum 
25(OH)D is the major circulating metabolite of vitamin D. Next, 25(OH)D circulates to 
the kidney and undergoes a second hydroxylation to give the biologically active form 
1,25-dihydroxyvitamin D3 (1,25(OH)2D)[2]. The half-life of serum 25(OH)D is 
approximately 3 weeks, whereas the half-life of  1,25(OH)2D is approximately four 
hours[4]. Serum or plasma 25(OH)D levels give the best single assessment of total body 
vitamin D status derived from the combination of cutaneous synthesis of VD3, dietary 
intake, and supplement use[4-7]. The papers included in this dissertation (Papers I-III) 
use serum 25(OH)D measurements to determine body vitamin D status (Methods 
Section 3.5).  
Vitamin D status is a topic of increasing clinical relevance and public health 
importance due to the resurgence of nutritional rickets in Europe and North America[8-
10], the high prevalence of hypovitaminosis D worldwide[11-15], and due to the 
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possible effect of vitamin D status on a number of chronic diseases[16]. The actions of 
vitamin D extend beyond bone health and mineral homeostasis[17] to include non-
classical molecular mechanisms that may play an important role in a range of diseases 
and non-skeletal health outcomes including cancer[18], auto-immune disease[19], 
cardiovascular disease[20], all-cause mortality[21], diabetes[22],  and respiratory 
disorders[23]. While it is widely accepted that a serum 25(OH)D level greater than or 
equal to 30nmol/L[24] is required for good bone health and the prevention of rickets, 
osteoporosis and osteomalacia[24-26], the minimum level of serum 25(OH)D needed 
for normal immune function[24, 27] or non-skeletal health outcomes such as asthma or 
allergy[28], has not yet been determined. Comparisons on the prevalence of vitamin D 
deficiency are difficult due to the lack of general consensus regarding cut-points used to 
determine a deficient level, and the inconsistent use of terminology to define these cut-
points. For example, a serum 25(OH)D level between 30-50nmol/L has been defined as 
“inadequate” [24], and levels below 50nmol/L have been defined as “deficient”[27], or 
“insufficient”[29]. Widely recommended cut-points to define vitamin D deficiency and 
insufficiency are serum 25(OH)D levels <50nmol/L, and <75nmo/L, respectively[17].  
The cut-points used in this dissertation (Papers I-III) are <25nmol/L, <50nmol/L, 
<75nmol/L and 75nmol/L, where <50nmol/L was considered deficient (Methods 
section 3.5). 
1.2  Factors associated with vitamin D status 
Low vitamin D status is prevalent world-wide[30], including sun-abundant 
countries[31-36] where urban living[31], gender[32, 33] ethnicity[34], and protective 
clothing associated with religious practice[35] or sun avoidance[36] are prominent. 
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Other determinants of vitamin D status include an individual’s location (latitude and 
altitude) and the duration and timing of outdoor activities dependent on season and time 
of day [37, 38]. The amount of UVB transmission capable of reaching the Earth’s 
surface is dependent on radiation path-length which is determined by solar zenith angle 
(SZA) [1, 38]. The SZA is a function of the Earth’s motion around the Sun on it’s own 
axis, in combination with the Sun’s position on the Earth’s surface, such that small 
SZAs occur during summer, at noon and at low latitudes, whereas large SZAs occur in 
winter, early morning/late afternoon and at high latitudes[1, 38]. At small SZAs the sun 
is high in the sky and solar radiation has a short path-length resulting in less chance of 
attenuation and greater opportunity for UVB radiation to reach the Earth’s surface[1]. 
At high latitudes, UVB radiation capable of cutaneous synthesis of vitamin D occurs 
during summer months at solar noon. The atmosphere (which decreases at high 
altitude), cloud cover, aerosol particles (related to urbanization and pollution), and 
ozone absorb UVB radiation which decreases the amount of available UVB for 
cutaneous synthesis of vitamin D[1, 38]. Another efficient absorber of UVB radiation is 
melanin content, which also determines human skin pigmentation[39].  Persons with 
increased melanin content (darker skin) require longer exposure to UVB radiation from 
the sun  in order to synthesize the same amount of cutaneous vitamin D compared to 
persons with lighter skin[39]. Consequently, immigration from sunny countries to new 
areas of higher latitude has increased public health concern regarding low vitamin D 
status of immigrant populations in some northern European countries, like Denmark[40] 
and Norway[41]. For example, the mean serum 25(OH)D level in Pakistani immigrants 
living in Oslo was 25.0±14 nmol/L compared to a mean serum 25(OH)D level of 
74.8±23.7 found in ethnic Norwegians[42]. In this study, the prevalence of serum 
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25(OH)D level <50nmoL was four times higher in Pakistani immigrants compared to 
ethnic Norwegians[42]. Diet and supplement use are particularly important when 
cutaneous synthesis of D3 is hampered or not possible[43-46]. Dietary sources of D3 
include oily fish and fish liver oil, egg yolk, shitake mushrooms, offal – such as liver, 
nutritional supplements, and fortified products such as dairy, juice, bread, cereal or 
infant formula[47-49]. In Norway only extra light milk and margarine are fortified with 
vitamin D[50], and a change away from more traditional dietary practices such as 
regular consumption of oily fish or regular intake of cod liver oil may be cause for 
concern[43, 51].  
Due to the fat soluble nature of 25(OH)D, body fat or high body mass index 
(BMI) is considered another factor associated with serum 25(OH)D level[52-54]. 
However,  the direction of the association between serum 25(OH)D level and BMI is 
still debated in the literature[55], and this will be further discussed in relation to 
findings from Paper I. Other behavioral factors related to vitamin D status include a 
sedentary lifestyle[56] and physical activity as either a proxy for leisure time spent 
outdoors[57], or as a factor independent of sun exposure[53]. Some studies have shown 
a positive association between smoking and vitamin D deficiency[58, 59] while others 
have found no association between smoking and vitamin D status[53, 60]. Finally, 
alcohol consumption has not been extensively studied and may also determine serum 
25(OH)D level[61].  
A recent systematic review of literature on vitamin D status in the Norwegian 
population based on 30 years of prior available data[13] summarized ten studies that 
gave direct estimates on the prevalence  of low vitamin D status, most of which were 
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conducted in infants, children, the elderly, or non-ethnic Norwegians. Only one study 
from northern Norway provided a direct estimate for the prevalence of low vitamin D 
status in a general adult population[62]. However, this study was restricted to women 
aged 44 to 59 years, and the plasma 25(OH)D variable was dichotomized as: 
<37.5nmo/L vs 37.5nmol/L, which greatly reduces comparability of findings. 
Noticeably missing from the literature is a well-designed prevalence study in a general 
population of Norwegian adults (men and women).  
Beyond filling a gap in the literature, an accurate estimate of the prevalence of 
vitamin D deficiency in a Norwegian general population is important for several 
reasons.  First, the majority of Norwegians reside at high latitudes where UVB light 
capable of activating the cutaneous synthesis of vitamin D is absent for a large part of 
the year. Also, there are very few food products fortified with vitamin D in Norway, and 
a change away from more traditional diet seems to  be underway in certain areas of the 
country[51]. Finally, increasing evidence suggests an association between vitamin D 
status and various health outcomes, including respiratory diseases such as asthma. 
1.3  Asthma and allergies 
Asthma is a heterogeneous disease with different underlying processes that is 
usually associated with airway hyper-responsiveness (AHR), and further characterized 
by chronic airway inflammation[63]. As a common chronic disease of the lungs, asthma 
is characterized by a history of respiratory symptoms which include recurrent attacks of 
wheezing, shortness of breath, tightness of the chest and cough, together with variable 
expiratory airflow limitation[63, 64]. An estimated 300 million people suffer from 
asthma worldwide[65], and an estimated 346,000 asthma-related deaths occur each 
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year[66], although most asthma-related deaths occur in low- and lower-middle income 
countries[64]. The prevalence of asthma is over 10% in Norwegian children and 
approximately 8% in Norwegian adults[67]. The socioeconomic burden of asthma is 
high including indirect costs, such as absenteeism or reduced performance at work, and 
direct medical costs associated with health services and medication use[68]. In 2011, 
asthma medicine dominated the list of medicines with the highest sales in Norway, 
topped only by medicines for rheumatoid arthritis[69].The daily cost for consumption of 
asthma medication in Norway was 3-16 NOK per patient in 2004[69]. Thus, asthma is 
not only a significant public health concern, but also a socioeconomic burden.  
Several asthma phenotypes have been identified including allergic asthma and 
non-allergic asthma[70, 71]. Allergic asthma is considered the most commonly 
identified asthma phenotype in children and can readily be associated with a history of 
allergic disease such as food or pollen allergy, or allergic dermitis[63, 71]. More than 
50% of asthma in adultsis also allergy-related. Meanwhile, 10-40% of adult patients 
with allergic rhinitis are estimated to have asthma[72]. Rhinitis is defined as irritation 
and inflammation of the mucous membrane of the nose[63]. Most patients with allergic 
asthma respond well to inhaled corticosteroid (ICS) treatment, whereas patients with 
non-allergic asthma seem to respond less well to ICS treatment[71]. Risk factors for the 
development or severity of asthma may include a range of host and environmental 
factors such as genetic predisposition, obesity, sex, allergens, infections, exposure to 
tobacco smoke, air pollution, diet, and stress[73]. To be noted, most knowledge on risk 
factors for asthma is based on studies from children, whilst risk factors for asthma in 
adults are less well known[63]. Suggested reasons for worldwide increases in asthma 
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and allergy include increased industrialization in developing nations and greater 
urbanization which contribute to increased air pollution and more time spent indoors. 
Consequently, vitamin D status might also play a role in the development of asthma and 
allergies.  
1.4  Vitamin D in relation to asthma and allergy  
 Due to its regulatory effect on the immune system, vitamin D may play an 
important role in the development and treatment of asthma and allergies[28]. To this 
end, several potential mechanisms on vitamin D and the risk of asthma and allergy have 
been suggested. In murine and humans models, vitamin D has been shown to enhance 
the generation of regulatory T cells[74, 75]. Regulatory T cells express inhibitory 
cytokines which can in turn inhibit T-helper(TH)1 and TH2 immune responses[76, 77]. 
Thus, vitamin D deficiency may be associated with reduced expression of the inhibitory 
cytokines which in turn increases risks of both TH1 mediated autoimmune diseases and 
Th2 mediated asthma or allergic diseases. Furthermore, low vitamin D status has been 
linked to enhanced oxidative stress[78] and increased airway smooth muscle (ASM) 
mass[79]. Additional mechanisms may include the regulation and expression of vitamin 
D pathway genes[80], production of cathelicidin, an antimicrobial polypeptide, in 
response to infections which may predispose children to develop asthma[81], and other 
effects on lung development and lung function that will be elaborated upon later.  
Scientific positions regarding the likely association between vitamin D status and 
the development of asthma or allergy are contradictory. On one side, Wjst and Dold 
have suggested the increased prevalence of asthma coincides with the fortification of 
food with vitamin D, and further assert that asthma is caused by vitamin D 
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supplementation[82]. Conversely, Litonjua and Weiss suggest asthma is caused by 
vitamin D deficiency given: (i) as populations grow and become more prosperous, more 
time is spent indoors leading to reduced exposure to UVB radiation; and (ii) inadequate 
intake of vitamin D from food or supplements results in vitamin D deficiency, 
particularly in pregnant women; which (iii) leads to more asthma and allergy in their 
offspring[28]. Several studies on maternal intake of vitamin D or infant 
supplementation with vitamin D in association with onset of wheeze, asthma or allergic 
conditions, have yielded conflicting results[83-88]. These studies relied on self-reported 
dietary intake of vitamin D and are limited by the lack of a direct measurement of 
25(OH)D. A recent review of vitamin D deficiency as a risk factor for childhood 
allergic disease and asthma[89] concluded that most cross-sectional and prospective 
studies have shown that  low vitamin D levels increase the risk of asthma and allergy in 
children[89], which supports the position that vitamin D deficiency may lead to 
asthma[28]. On the contrary, some studies presented in this review suggest an 
association between high 25(OH)D and  increased  risk of childhood asthma and allergy 
in children[89], which supports the position held by Wjst and Dold[82]. Data from 
small clinical trials included in this review suggest that vitamin D supplementation may 
decrease the risk for asthma exacerbations and severity of eczema in children[89]. 
Before firm recommendations can be made on vitamin D supplementation for children 
with asthma or allergy, results from large clinical trials of long duration must be 
considered. 
To date, very few studies on vitamin D status and asthma development in adults 
have been published[90-92]. A cross-sectional study using data from the National 
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Health and Nutrition Examination Survey (NHANES 2005-2006) reported an 
association between low serum 25(OH)D level and greater odds of asthma diagnosis in 
non-atopic individuals[90]. This was in line with a previous finding from our research 
group of an association between low serum 25(OH)D level and incident asthma in men 
without allergy[91]. However, a more recent study using data from the Korean National 
Health and Nutrition Examination Survey (KHANES 2008-2010) found subjects with 
lower serum 25(OH)D level had increased likelihood of atopic dermatitis, but not 
asthma or allergic rhinitis[92]. Despite the large sample size of the KHANES study, the 
cross-sectional design is a limiting factor. The evidence for an association between 
vitamin D status and allergy in adults is also lacking. One study using NHANES (1988-
1994)  data, found an increase in the prevalence of allergic rhinitis across 25(OH)D 
quartile groups in all ages, but with more prominent effects in children[93]. Findings 
from our research group showed that serum 25(OH)D level<50nmol/L was associated 
with increased risk of allergic rhinitis in men, but a reduced risk in women to suggest 
vitamin D status may play different roles in the development of allergic rhinitis among 
men and women[94]. Data from the UK showed a U-shape association between serum 
25(OH)D levels and immunoglobulin (Ig)E levels to suggest a threshold effect of both 
upper (>135 nmol/L) and lower (<25nmol/L) serum 25(OH)D with increasing levels of 
IgE concentration[95]. This threshold effect may have important implications regarding 
adverse allergy risk for ongoing trials with high vitamin D supplementation. Still, due to 
the paucity of evidence in general adult populations, it is not possible to draw a 
conclusion on the relationship between vitamin D status and development of asthma or 
allergy.  
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To date, few studies on vitamin D status and asthma severity have been 
published, and most were done in children[96-100]. Brehm et. al, first studied the 
association between measured 25(OH)D and markers of asthma severity in children[96]. 
In 616 Costa Rican children aged 6 to 14 years, lower levels of 25(OH)D were 
associated with increased markers for allergy and asthma severity such that a log 10 unit 
increase of 25(OH)D was associated with reduced odds of any hospitalization in the 
previous year, any use of anti-inflammatory medication in the previous year, and 
increased airway responsiveness[96]. Brehm et.al, further assessed the relationship 
between serum 25(OH)D and severe asthma exacerbations in North American children 
with mild-to-moderate persistent asthma and found similar results[97]. In this 
population, vitamin D insufficiency (serum 25(OH)D<75nmol/L) was associated with 
higher odds of any hospitalization or emergency department visit over a 4 year 
period[97]. Another North American study in children with asthma (n=100) found that 
lower serum 25(OH)D levels in asthmatic patients were associated with increased 
corticosteroid use and worsening airflow limitation[98]. One additional study on the 
relationship between serum 25(OH)D level, disease severity, and airway remodeling in 
children with asthma found a higher prevalence of lower serum 25(OH)D levels in 
children with therapy-resistant asthma[99]. In this study, low vitamin D status was also 
associated with increased acute asthma exacerbations in the previous 6 months[99]. 
Despite the mounting evidence on vitamin D status and asthma severity in children, few 
studies in adults with asthma have been conducted. Regarding asthma severity, lung 
function measures are associated with future exacerbations of asthma symptoms and can 
therefore partly determine asthma control[63]. Studies on vitamin D status and lung 
function in general and asthma populations will be further discussed below.  
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1.5 Vitamin D in relation to lung function  
Asthma is characterized by expiratory lung function (LF) that varies over 
time[63]. In any given patient with asthma, LF may vary from well-controlled to 
severely obstructed, in a reversible manner. The use of spirometry to measure LF, 
particularly forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) 
and FEV1/FVC ratio  is an important method to assess airflow limitation in obstructive 
asthma. LF measures are associated with future exacerbations of asthma symptoms 
apart from current smoking and poor medication adherence[63, 101]. In healthy adults, 
the FEV1/FVC ratio is normally greater than 0.75-0.80, and values less than this 
indicate airflow limitation[63]. Chronic obstructive pulmonary disease (COPD), which 
is further discussed below, is characterized by a fixed airflow obstruction with 
FEV1/FVC<0.70[102]. It has been suggested that serum 25(OH)D levels may influence 
LF or LF changes through modulation of fibroblasts in respiratory epithelial cells[103], 
and by mediating the contraction, inflammation and remodeling of ASM function[79].  
Several studies have shown an association between low vitamin D status and lower LF 
in general adult populations[104-108], among which, two studies have suggested a 
potentially stronger association in men compared to women[106, 108]. Most of these 
previous studies found associations between serum 25(OH)D level <50nmol/L and 
lower FEV1 and FVC, but not FEV1/FVC ratio, as might be expected in studies based 
on adult general populations rather than asthma or COPD cohorts. Studies on vitamin D 
status and LF in asthma populations are limited.  One cross-sectional study of Costa 
Rican children with asthma (n=287) showed an association between serum 25(OH)D 
level<75nmol/L and lower FEV1/FVC ratio[109]. An observational study of 54 adult 
patients with persistent asthma in the US, reported an association of reduced continuous 
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serum 25(OH)D with impaired FEV1 and increased AHR[110]. In this study, adult 
asthma patients not treated with ICS seemed to be more responsive to the beneficial 
effects of a higher serum 25(OH)D level[110]. A recent cross-sectional study of 
Chinese adults with asthma (n=435) found a significant association between vitamin D 
deficiency (<50nmol/L) and low values for FEV1/FVC ratio and FEV1[111]. However, 
this study did not report sex-specific results.  
As previously mentioned, sex is one risk factor for asthma[73]. In children, the 
prevalence of asthma is nearly twice as high in boys compared to girls[112]. With 
increasing age, the sex difference in the prevalence of asthma narrows until adulthood 
when the prevalence of asthma is greater in women than in men[63]. One possible 
explanation for a sex-differentiated prevalence of asthma is due to lung size and the 
potential for airway volume which is smaller in male compared to female infants[113], 
but larger in male compared to female adults[101]. At least one study showed an 
association between low serum 25(OH)D and incident asthma in adult men but not 
women[91]. Further sub-group analysis revealed this association to be in men without 
allergy status[91]. In addition, results derived from NHANES data (2005-2006) showed 
an association between lower serum 25(OH)D levels and greater odds of asthma 
diagnosis in non-atopic individuals [90]. Taken together, vitamin D status seems to be 
associated with asthma onset via a non-allergic pathway.  However, evidence regarding 
the possible pathway by which vitamin D deficiency may be related to asthma severity 
and control in adults is lacking. Furthermore, the temporal relationship between vitamin 
D status and LF changes in adults, with or without asthma, requires further 
investigation.  
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To date, only three prospective studies on vitamin D status and LF changes in 
general adult populations have been published[105, 114, 115], and results from these 
studies do not concur with each other. One Danish study by Thuesen et al., (n=4,999) 
found a significant cross-sectional association between low serum 25(OH)D levels and 
a higher proportion of low FEV1 percent predicted (% pred.) defined as less than (<) 
80%, but a prospective association between high serum 25(OH)D levels and adverse LF 
changes[114]. In contrast, a second Danish study by Afzal et al., found a prospective 
association between lower plasma 25(OH)D and more LF decline (FEV1 % pred., FVC 
% pred., but not FEV1/FVC ratio)[115]. Results from this study were independently 
replicated in two general populations (n=10,116 and n=8,391). Some of the differences 
in results between these two Danish studies may be explained by method-related 
differences based on different assays used for measurement of serum 25(OH)D 
levels[116]. Finally, a smaller prospective study of elderly men (n=626) in the US found 
an association between vitamin D deficiency (<50nmol/L) and lower LF as well as 
increased LF decline in current smokers[105]. In all three prospective studies, smoking 
status (daily, current or continuous vs. never) showed a tendency toward a larger effect 
estimate of the association between serum 25(OH)D levels and LF changes[114], or 
modified the association between serum 25(OH)D and LF decline[105, 115]. Based on 
the current state of evidence, the association between serum 25(OH)D level and LF 
changes in the general population remains unclear, but smoking status seems to be an 
important covariate for consideration.  
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1.6  Chronic Obstructive Pulmonary Disease (COPD) 
COPD is a common and preventable disease in adults that is characterized by 
persistent airflow limitation according to a fixed ratio of post-bronchodilator 
FEV1/FVC<0.70[102]. Some suggest that FEV1/FVC<LLN may be an alternative 
diagnostic criteria for COPD[117]. However, expert-diagnosis in clinical practice is 
best, as the fixed ratio may over-diagnose COPD, while LLN definitions will likely 
under-diagnose COPD, particularly in elderly persons[118]. COPD is further 
characterized by a history of respiratory symptoms which include dysponea (breathing 
discomfort), chronic cough, chronic bronchitis, wheezing, and tightness of chest[102]. 
Diagnostic differentiation between asthma and COPD may be difficult and these 
conditions may overlap (asthma-COPD overlap syndrome, or ACOS), particularly in 
older persons or current and former smokers[63]. COPD is usually progressive and is 
associated with enhanced chronic airway inflammation in response to noxious particles 
or gases[102]. Smoking is the main risk factor for COPD[119], and COPD continues to 
be a global burden in terms of morbidity, mortality, and health-care costs[120]. 
1.7  Vitamin D in relation to smoking and COPD 
The harmful consequences of smoking on lung health are well understood, and 
mechanisms by which cigarette smoke contributes to lung disease include oxidative 
stress and pro-inflammatory responses in lung cells[121].  Both of these mechanisms 
may be modulated by vitamin D[122, 123]. Lung epithelial cells generate active vitamin 
D which influences the expression of the vitamin D receptors (VDR) to mediate gene 
expression and modulate these biological effects[124]. Experimental design has shown 
that cigarette smoke extract can decrease conversion of inactive to active vitamin D in 
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the lungs[125]. Reduced local activation of vitamin D can impact the maintenance of 
barrier cell function in the lungs[126]. More specifically, vitamin D can regulate 
prostaglandin E2 to modulate lung fibroblasts which play a critical role in lung tissue 
repair and remodeling[127]. Lower levels of active vitamin D in the lungs of  smokers 
will consequently reduce barrier function by decreasing repair and remodeling of 
epithelial cells in the airway, increasing chemokine expression, and increasing local 
inflammation. Cigarette smoke can also directly induce systemic inflammation[128] and 
increased systemic inflammation has been linked to greater LF decline[129]. On the 
other hand, higher serum 25(OH)D levels may decrease circulating levels of 
chemokines and cytokines to reduce systemic inflammation[130]. Whereas, attenuation 
of airway inflammation via vitamin D is impaired in persons with lower serum 
25(OH)D levels[131].      
Beyond the risk of smoking, and the molecular mechanisms of vitamin D in 
relation to smoking and lung function decline, other factors that could explain low 
vitamin D status in COPD patients include but may not be limited to, poor diet, reduced 
outdoor activity and therefore less sun exposure, and reduced capacity for cutaneous 
synthesis of vitamin D due to aging skin[132].   
An out-patient study in Denmark (n=62) reported a 68% prevalence of 
osteoporosis or osteopenia in COPD patients[133]. A high prevalence of bone disease 
suggests an equally high prevalence of vitamin D deficiency in this COPD population. 
In a more recent genotyping study, vitamin D deficiency (serum 25(OH)D<50nmol/L) 
was highly prevalent in COPD patients (60% to 77%, depending on disease severity) 
and was correlated with variants in the vitamin D binding protein[134]. It seems that 
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patients with severe COPD may be a good target for vitamin D supplementation, but the 
evidence on vitamin D supplementation or vitamin D status and disease severity or 
exacerbations, is conflicting. For example, high doses of vitamin D supplementation 
(100,000 IU every 4 weeks for 1 year) did not reduce the incidence of COPD 
exacerbations in a  randomized trial of participants (n=182) with moderate to very 
severe COPD and a history of recent exacerbations[135]. However, a post hoc analysis 
of 30 trial participants with serum 25(OH)D level<25nmol/L at baseline did show a 
decrease in incidence of COPD exacerbations in those that received vitamin D 
supplementation compared to placebo[135]. The single-centre design of this trial may 
be a limiting factor. In addition, results from a nested, matched case-control study of 
continuous smokers (n=196), found no association between baseline serum 25(OH)D 
levels and subsequent lung function decline in slow versus rapid decliners[136]. 
However, due to the small sample size, this study may have limited variation in serum 
25(OH)D levels.   
The state of evidence is further confused given results from a UK population-
based study[137]. The authors found high dietary intake of vitamin D to be associated 
with better lung function and decreased prevalence of COPD. However, no associations 
between serum 25(OH)D level (the gold standard to determine total body vitamin D 
status) and lung function  were observed. The authors finally conclude that vitamin D 
status is not an important determinant of lung function or COPD in the general UK 
population[137]. A  most recent prospective study by Afzal et al., reported a  significant 
finding amongst smokers with an association between  lowest quintiles of plasma 
25(OH)D and higher risk for development of COPD[115]. Although these findings were 
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replicated in two general populations with large sample sizes (n=10,116 and n=8,391), 
this study has been critiqued by Young and Hopkins[138] who believe the findings may 
be spurious.  First, they suggest the association between  serum 25(OH)D level and lung 
function may be subject to a threshold effect[138]. Second, they cite concern with the 
fact that the overall estimates for an association between vitamin D status and FEV1 % 
pred. were consistently mirrored by a corresponding association between vitamin D 
status and FVC % pred., but no effect was observed for FEV1/FVC ratio[138, 139]. In 
response to this critique, Afzal et. al purport  that the observed significant interaction 
suggests  a stronger association between vitamin D status and FEV1% pred. in 
individuals with airway obstruction[139]. Additional prospective and intervention 
studies on vitamin D status and lung function with regards to onset and severity of 
COPD are needed. If better vitamin D status could improve accelerated lung function 
decline amongst smokers, the burden of COPD may be reduced. 
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2 Research aims 
 
The research aims for Papers I-III included in this doctoral dissertation  are: 
 
1) To estimate the prevalence of, and identify factors associated with vitamin D 
deficiency (serum 25(OH)D level <50nmol/L) in a Norwegian adult population; 
  
2) To investigate the associations between serum 25(OH)D level and lung function 
in an adult asthma cohort, and to explore potential effect modification by sex 
and allergy status; and 
 
3) To investigate the interrelationship between serum 25(OH)D level, smoking and 
lung function or lung function changes in a general Norwegian adult population.  
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3 Methods 
3.1 The Nord-Trøndelag Health (HUNT) Study  
Nord-Trøndelag county is one of 19 counties in Norway that is further divided 
into 23 municipalities. The county is centrally located at latitude 64° North. County 
population statistics (1995-2008) report a stable population of approximately 134,000 
inhabitants with low net migration of 0.3%[140]. The county population is mostly 
Caucasian (97%), with socio-demographic characteristics, as well as morbidity and 
mortality profiles considered generally representative of Norway[141]. The HUNT 
Study is one of the largest population health studies conducted in Norway to date. Three 
adult HUNT surveys have been completed: HUNT1 (1984-1986), HUNT2 (1995-1997), 
and HUNT3 (2006-2008)[141, 142]. Planning for HUNT4 is currently underway, and 
data collection is expected to begin in 2017[143]. 
3.1.1 The HUNT2 Survey 
Between August 1995 and June 1997, all residents of Nord-Trøndelag County 
aged 19 years and older, were invited to participate in HUNT2 via invitation letter sent 
to the home address of each potential participant[141, 142]. The invitation file was 
created from periodically updated census information provided by Statistics Norway. 
The first questionnaire (H2-Q1) was attached to the invitation letter and each potential 
participant was asked to self-administer and complete H2-Q1 prior to attending a 
clinical examination. H2-Q1 data included information on socio-demographics, lifestyle 
factors, history of asthma and allergy, as well as medication use. At the clinical 
examination, anthropometric data was collected including height and weight. A blood 
sample was also collected and stored at -70° Celsius for future use. At the clinical 
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examination, participants received a second questionnaire (H2-Q2) to be self-
administered, completed at home and returned by mail in a pre-stamped envelope. The 
target population for HUNT2 consisted of  93,898 adults and the participation rate was 
69.5% (n=65,237)[141, 142]. 
3.1.2 The HUNT2 Non-Responder Survey 
A random sample of 2.5% of HUNT2 non-responders (n=26, 000) were invited 
to participate in a telephone survey[144]. Potential participants to the HUNT2 non-
responder survey were contacted by telephone. If no telephone contact was made after 
three attempts on three separate dates, the H2-Q1 was mailed by post to the potential 
participant. Of the 685 potential participants for the HUNT2 non-responder survey, 
approximately 50% (n=326) gave consent to the telephone interview or completed and 
returned H2-Q1 which was received by mail. In the 20-69 year age group, the most 
cited reason for non-response to HUNT2 was lack of time or moved away (54%)[144]. 
Other reasons given for non-response included time consuming examinations and 
absence from work. A significantly higher proportion of current smokers was found in 
the non-responder group compared to current smokers in the responder group (current 
smokers: 36% of non-responders vs. 30% of responders). However, no significant 
difference in prevalence of self-reported asthma or use of asthma medication was found 
between non-responders and responders in the HUNT2 survey[144].  
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3.1.3 The Lung Health Study 
Among those who participated in the adult HUNT2 survey, two sub-groups were 
invited to participate in the Lung Health Study (LHS), including: (1) a 5% random 
sample of total responders from the HUNT2 survey; and (2) a symptom group of 
HUNT2 participants who answered affirmatively to ever asthma, ever use of asthma 
medication, or attacks of breathlessness or wheezing in the past 12 months[145].  The 
LHS consisted of flow/volume spirometry and a structured personal interview on 
respiratory symptoms, diagnosis and treatment[145]. As part of HUNT3, a second LHS 
was conducted, where persons who participated in HUNT2-LHS were followed up, and 
a new 5% random sample of total responders from HUNT3 was invited to participate in 
the HUNT3-LHS. 
3.1.4 The HUNT3 Survey 
Between October 2006 and June 2008, all residents of Nord-Trøndelag County 
aged 19 years and older were invited to participate in HUNT3. The methods of data 
collection were similar to HUNT2.  Data collected from H3-Q1 included information on 
socio-demographics, lifestyle factors, history of asthma and allergy, medication use, but 
also included questions related to culture and religion[142]. At the clinical examination, 
anthropometric data was collected including height and weight. Blood and urine 
samples were  collected and given high priority as part of the establishment of the 
HUNT Biosciences bio-bank[142]. The target population for HUNT3 consisted of 
93,860 adults and the participation rate was 54.1% (n=50,807). Among the adult 
HUNT2 participants, 57% (n= 37,059) were followed up to HUNT3[142].  
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3.1.5 The HUNT3 Non-Responder Survey 
Approximately nine months after completion of the HUNT3 survey, a short two-
page questionnaire was sent to all HUNT3 non-responders (n=42,024) amongst whom 
17% completed the nonparticipation questionnaire[146]. The questionnaire included 
several of the core H3-Q1/H3-Q2 questions as well as questions related to reasons for 
non-response. Nearly 10% of non-responders reported they had not received the 
HUNT3 questionnaire. Otherwise, the dominant reason for non-participation of persons 
aged 20-59 years was lack of time or inconvenient session (55%-65% depending on age 
and sex). A significantly lower proportion of never smokers was found in the non-
responder group compared to never smokers in the responder group (never smokers: 
43% of non-responders vs. 46% of responders)[146]. Regarding prevalence of self-
reported asthma, there was no significant difference between non-responders and 
responders in the HUNT3 survey. However, ever COPD was reported more frequently 
in male non-responders compared to male responders, whereas no substantial 
differences in women with COPD were found between non-responders and 
responders[146]. 
3.2 Analysis cohorts 
This doctoral dissertation and papers herein are based on secondary analyses of 
primary data collected from HUNT2, HUNT2-LHS, HUNT3, and HUNT3-LHS. Figure 
1 is a pictorial representation of the analysis cohorts used in Papers I-III which are 
further described in the text below. 
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3.2.1 Paper I 
The analysis cohort for Paper I is based on a 10% random sample of participants 
(n=2584) from a cohort of adults aged 19-55 years who participated in both HUNT2 
and HUNT3 (n=25, 616). These participants were selected for measurement of serum 
25(OH)D from blood samples collected in HUNT2. In total, 97% of subjects (n=2505) 
had sufficient serum volume for analysis. This 10% random sample represents the 
general HUNT population[147].  
3.2.2 Paper II 
The analysis cohort for Paper 2 is based on an asthma cohort selected from the 
total cohort who participated in both HUNT2 and HUNT3 (n=25,616). The asthma 
cohort of adults aged 19-55 years in HUNT2 (n=898) was selected based on persons 
who answered affirmatively to both of the following two questions in HUNT2: “Have 
you had attacks of wheezing or breathlessness during the last 12 months?” and “Do you 
have or have you ever had asthma?” In order to strengthen the classification of their 
asthma status, persons selected into the asthma cohort also provided an affirmative 
response to the ever asthma question in HUNT3. Serum 25(OH)D levels were measured 
in this asthma cohort from blood samples collected during HUNT2. Lung function 
measures for Paper II were based on spirometry data collected from the symptom group 
during the HUNT2-LHS (Figure 1). 
3.2.3 Paper III 
The analysis cohort for Paper 3 is based on the 10% random sample of serum 
25(OH)D measurements from HUNT2, as in Paper I. Lung function measures for Paper 
III were available from the 5% random sample group during HUNT2-LHS. Follow-up 
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spirometry in this 5% random sample group was also available from HUNT3-LHS. 
Persons aged 19-55 years with complete data on serum 25(OH)D level and lung 
function in HUNT2  were included in the cross-sectional study (n=1293). Seventy 
percent of participants from the cross-sectional study (n=922) were followed up with 
complete lung function data in HUNT3 (figure 1). 
25 
 
Figure 1 Analysis cohort selection, the HUNT Study, 1995-1997 to 2006-2008.  
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HUNT: Nord-Trøndelag Health Study; HUNT 2, 1995-1997; HUNT 3, 2006-2008; 25(OH)D: 
25-hydroxyvitamin D; LHS: Lung Health Study; LF:  lung function. 
 
Paper III cross-sectional study 
Serum 25(OH)D measurements 
 10% random sample n=2,505 
LF measured in H2-LHS 
 complete serum 25(OH)D and LF  
n=1,293 
Paper III prospective study 
Serum 25(OH)D measurements 
 10% random sample n=2,505 
LF measured in H3-LHS 
 5% random sample H2-LHS followed-up 
 complete serum 25(OH)D and LF 
n=922 
Attended H2 screening, completed H2-Q1 
n=65,237 (70%)  
Participated in both H2 and H3 
n=37,059 
Overall cohort population 
 Participated in both H2 and H3 
 Aged 19-55 years in H2 
n=25,616 
Paper I general population 
Serum 25(OH)D measurements 
 10% random sample n=2,584 
 complete serum 25(OH)D n=2,505 
 
Invited Adult HUNT2 (H2) 
n=93,898 
Invited Adult HUNT3 (H3) 
n=93,860 
Attended H3 screening, completed H3-Q1 
n=50,807 (54%) 
Invited H2-LHS 
 5% random sample (n=3,296) 
 Symptom group (n=10,063) 
Participated H2-LHS 
 5% random sample n=2,791 (85%) 
 Symptom group n=8,150 (80%) 
 
Paper II asthma cohort 
 Asthma cohort n=898 
 complete serum 25(OH)D n=858 
LF measured in H2-LHS 
 complete serum 25(OH)D and LF 
n=760 
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3.3 Serum 25(OH)D measurements 
Blood samples were collected in HUNT 2 and stored at -70°C for later use. 
Serum 25(OH)D levels were measured using a fully automated antibody-based 
chemiluminescence assay (LIASON 25-OH Vitamin D TOTAL; DiaSorin, Saluggia, 
Italy) with detection range 10-375nmol/L, intraassay coefficient of variation (CV) 4%, 
and interassay CV 8%. Assay imprecision was evaluated and in compliance with 
standards according to CLSI EP5-A2[148, 149]. The stability in different markers in 
serum from HUNT2 has been questioned due to high probability of longer stay in room 
temperature than recommended for blood handling[150]. However, the pre-analytical 
stability of 25(OH)D in blood samples at room temperature is said to be stable[151].    
From the 10% random sample of the overall cohort participants (n=2584), 97% 
of subjects (n=2505) had sufficient serum volume for analysis (Figure 1). Serum 
25(OH)D levels ranged from 10 to 251 nmol/L. Circulating levels of serum 25(OH)D 
are indicative of bioavailable vitamin D status[4, 7]. A serum 25(OH)D level between 
30-50nmol/L has been described as inadequate[24] and levels below 50nmol/L have 
been defined as deficient[27] or insufficient[29]. The cut-points for serum 25(OH)D 
levels used in this dissertation (Papers I-III) are <25nmol/L, <50nmol/L, <75nmol/L 
and 75nmol/L, where <50nmol/L was considered deficient.  
3.4 Lung function measurements 
Lung function measures were collected during the HUNT2 Lung Health Study 
(LHS) and HUNT3-LHS, and consisted of flow/volume spirometry recorded using two 
MasterScope Jaeger v.5.1 by trained professionals at screening stations. Instrument 
quality control included twice daily calibration. Biological control was conducted once 
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daily via staff lung function assessment. Participants were made to sit upright and use a 
nose-clip[152]. Recommendations and criteria from the American Thoracic Society 
(ATS) were followed and applied[153]. Participants were required to give three to five 
acceptable and reproducible trials during which expiration continued for at least six 
seconds. The best trial was determined by identification of the flow/volume curve using 
the highest sum of FEV1 and FVC. The acceptability and reproducibility of results were 
reviewed by expert technicians.  In the HUNT surveys, the curves with the highest sum 
of FEV1 and FVC, and the best FEV1/FVC ratio were used. Predicted reference values 
were derived from the prediction equations of spirometry based on the same HUNT 
population[152], and these predicted values were used to calculate FEV1 % pred., FVC 
% pred., and lower limit of normal (LLN). Lung function impairment was defined as 
FEV1/FVC ratio<70% or FEV1/FVC ratio<LLN based on prior literature and on 
recommendation by the ATS[101, 153]. 
3.5 Other study variables 
Data on all other study variables were collected by questionnaire and clinical 
examination in HUNT2 or HUNT3, with the majority of data used from HUNT2. 
Categorization of these study variables was consistent across Papers I-III unless 
otherwise stated. Missing data was categorized as unknown and included in the analyses 
unless otherwise stated in statistical methods (Section 3.8).  
3.5.1 Socio-demographic variables 
Age at time of invitation was included as a categorical  (19-29, 30-39, 40-49 or 
50-55) (Paper I) or continuous (Papers  II and III) variable. Sex was dichotomized as 
male or female. Socio-economic variables included years of education (Paper I: <10, 
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10-12, 13 or unknown; Paper II: <10, 10 or unknown), receipt of social benefits 
(Papers I and II: yes, no or unknown), and economic difficulty in the last year (Papers I 
and II: yes, no or unknown). For Paper III, we generated a new variable for socio-
economic status (SES) (high, low or unknown). High SES included non-recipients of 
social benefits and/or persons with no economic difficulties in the last year, while low 
SES included recipients of social benefits and/or persons with economic difficulties in 
the last year. Receipt of social benefits was determined based on participant response to 
the following HUNT2 question, “Do you receive any of the following public welfare 
benefits? Sick pay, rehabilitation benefits, retraining benefits, disability pension, 
retirement/old age pension, family income supplement, unemployment benefits, 
transitional benefits, widow’s pension, other benefits.” Economic difficulty in the last 
year was defined by participant response to the following HUNT2 question, “During the 
last year, has it at any time been difficult to meet the costs of food, transportation, 
housing and such?” 
3.5.2 Season  
Season of blood sample collection was categorized according to the Norwegian 
Meteorological Institute standard: summer (June through August), autumn (September 
through November), winter (December through February) or spring (March through 
May)[154] (Paper I). For Papers II and III, season was dichotomized as December 
through May or June through November.  
3.5.3 Body mass index (BMI) 
Body weight and height were measured in clinical examination by trained 
personnel at HUNT2 screening stations. Height was measured to the nearest centimetre 
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(cm) and weight to the nearest half-kilogram (kg)[141]. BMI was calculated as weight 
in kilograms divided by height in meters squared (kg/m2). For Paper I, BMI was 
categorised according to  the World Health Organization standard (<25.0, 25-29.9, 
30.0  or unknown)[155]. For Papers II and III, BMI was included in the analyses as a 
continuous variable.  
3.5.4 Lifestyle variables  
Average number of hours of light physical activity per week was categorized as 
<1, 1-3, 3 or unknown (Paper1). For Papers II and III, light physical activity was 
categorized as <1, 1 or unknown hours per week. Physical activity was defined based 
on participant response to the following HUNT2 question: “How much of your leisure 
time have you been physically active during the last year? (Think of a weekly average 
for the year. Your commute to work counts as leisure time)” Participants qualified their 
physical activity as light (no sweating/not out of breath) or vigorous (sweating/out of 
breath).  Daily smoking was categorized as never, current, former or unknown (Papers I 
and II). For Paper III, daily smoking was categorized as never or ever (current/former). 
Frequency of alcohol consumption was based on participant response to the following 
question, “How many times a month do you normally drink alcohol?”, and was 
categorized in Paper I as abstain/once, 1-4, 5 or unknown. 
3.5.5 Allergy status 
 In Paper II, allergic rhinitis was used as a proxy measure for allergy status (yes, 
no or unknown) based on participant response to the following HUNT3 question, “Do 
you have or have you had allergic rhinitis or hay fever?” 
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3.5.6 Medication and supplement use 
Daily intake of cod liver oil (5mL/400 IUs of vitamin D per day by 
recommendation) for at least one month was categorized as yes, no or unknown (Paper 
I). For Paper 2, ever use of asthma medication was included as yes, no or unknown. 
Also for Paper 2, regular use of inhaled corticosteroids (ICS) in the last 6 months was 
dichotomized as yes or no, and daily dosage of ICS was included as a continuous 
variable in a sensitivity analysis.  
3.6 Statistical methods 
STATA versions 12.1 and 13.1 were used for all statistical analyses (StataCorp LP, 
College Station, Texas).  
3.6.1 Paper I 
In this study, we estimated the prevalence of vitamin D deficiency (serum 
25(OH)D <50nmol/L) in a general Norwegian population (n=2505) and examined 
factors associated with serum 25(OH)D level and vitamin D deficiency using a random 
sample and cross-sectional study design. We calculated the prevalence of vitamin D 
deficiency overall and by season of blood sample collection, and demonstrated the 
frequency distribution of serum 25(OH)D levels by histogram. We used Poisson 
regression[156] to estimate the crude and adjusted prevalence ratio (PR) and 95% 
confidence intervals (CIis) of factors associated with vitamin D deficiency. Analysis of 
variance was used to calculate the mean difference in serum 25(OH) D level by socio-
demographics, season, BMI and lifestyle variables. We used Fischer’s exact test for 
small sample sizes to test differences in baseline characteristics between those with 
serum 25(OH)D level <25nmol/L compared to the 25nmol/L group. The multivariable 
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models included age, sex, education, receipt of social benefits, economic difficulties, 
season of blood sample collection, BMI, cod liver oil intake, physical activity, smoking 
and alcohol consumption. Missing data for education, social benefits, economic 
difficulties, BMI, cod liver oil intake, physical activity, smoking, and alcohol 
consumption were categorized as “unknown” and included in the analysis. Missing data 
were assumed missing at random (MAR). In addition, we used the multivariate 
imputation by chained equations (MICE) method to impute fifty datasets of missing 
data on the above covariates and repeated the analyses. 
3.6.2 Paper II 
In this cross-sectional observational study, we assessed the association between 
serum 25(OH)D level and lung function in Norwegian adults with asthma (n=760). We 
also examined possible interactions by sex and allergy status. Based on our hypothesis, 
we used the likelihood ratio test to evaluate the modifying effect of sex and allergy 
status on lung function .  Based on a significant three-way interaction term (categorical 
serum 25(OH)D*sex*allergic rhinitis) on lung function parameters (p=0.03) we 
performed the analysis separately in women (n=446) and men (n=314), and further 
stratified the data by allergic rhinitis. We used Pearson’s chi-squared to test differences 
between baseline characteristics in women compared to men in the analysis group. 
Further, we used Pearson’s chi-squared to test differences between baseline 
characteristics in the analysis group compared to participants excluded due to missing 
information on either exposure or outcome (n=138). We used linear regression analysis 
to estimate the association between serum 25 (OH)D levels and lung function measures 
(FEV1 % pred., FVC % pred., and FEV1/FVC ratio). Serum 25(OH)D level was 
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analyzed as either a categorical (<50 nmol/L, 50-74.9 nmol/L or 75nmol/L) or 
continuous independent variable. Crude and adjusted regression coefficients (ȕ) and 
95% CIis are given. Multivariable linear regression models included BMI, education, 
receipt of social benefits, economic difficulties in the last year, season of blood sample 
collection, physical activity, smoking status, ever use of asthma medication and regular 
use of ICS in the last 6 months as important covariates. Missing data on education, 
social benefits, economic difficulties, physical activity, smoking status and ever use of 
asthma medication were categorized as “unknown” and included in the analysis. 
Missing data were assumed MAR. We used the MICE method to impute fifty datasets 
of missing data on the above covariates and repeated the analyses. To minimize possible 
misclassification of reported asthma, we excluded those who reported having COPD, 
chronic bronchitis or emphysema (n=83) and repeated the analysis.  
3.6.3 Paper III  
In this observational study, we assessed the cross-sectional (n=1220) and 
prospective (n=869) interrelationship between serum 25(OH)D level, smoking and lung 
function or lung function changes in a random sample of Norwegian adults. The 
analyses were performed overall and separately in never and ever smokers, based on 
priori information from the literature, and our hypothesis. We used multivariate linear 
and logistic regression analyses to estimate the crude and adjusted differences in LF or 
LF decline, crude and adjusted odds ratios (ORs) for LF impairment or development of 
LF impairment, and 95% CIs. We conducted the analyses using serum 25(OH)D level 
as a categorical (<50nmol/L or 50nmol/L), or continuous independent variable. 
Outcome measures for linear models included continuous values of FEV1 % pred., FVC 
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% pred., and FEV1/FVC ratio. Outcome measures for logistic models included 
FEV1/FVC ratio <70% and FEV1/FVC ratio <LLN. T FEV1/FVC ratio models based on 
actual measurements rather than predicted equations were further adjusted for age, sex 
and height. Multivariable linear and logistic regression models included BMI, 
education, socio-economic status, season of blood sample collection and physical 
activity as important covariates. Missing data on socio-economic status, and physical 
activity were categorized as “unknown” and included in the analyses. After participants 
with complete data on serum 25(OH)D,  smoking, and lung function were included in 
the studies, missing data on the above covariates was less than 2%, therefore, multiple 
imputations of missing data were not performed. To minimize possible residual 
confounding, we further controlled for pack-years of smoking as a continuous variable 
amongst ever smokers. To test the robustness of our findings, we excluded subjects who 
reported ever asthma (n=110), ever COPD (n=10), or both (n=12), and repeated the 
analyses.  
3.7 Ethics 
The HUNT Study including all adult HUNT surveys, non-response surveys and 
sub-studies (Lung Health Study), received ethics approval from the Regional 
Committee for Ethics in Medical Research (REK), and the Norwegian Data 
Inspectorate. All participants gave informed written consent.  
This doctoral research received ethics approval from the REK and utilized data 
and blood samples that had already been collected by the HUNT Research Center. All 
names and personal identification were removed from the data files received from the 
HUNT Research Center. Only anonymous case numbers were used to link questionnaire 
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data and biological samples. Thus, the anonymity of all study participants was 
protected. No persons were directly contacted and no new information was gathered as 
part of this doctoral research. The values of serum 25(OH)D were not provided to study 
participants.  
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4 Results 
4.1 Factors associated with vitamin D deficiency in a Norwegian 
population 
Using data from the HUNT Study, we estimated the overall prevalence of 
vitamin D deficiency to be 40%, ranging from 20% in the summer to 64% in the 
winter (p<0.001). Winter season (adjusted prevalence ratio (PR): 3.16, 95% CI: 1.45-
2.10) and obesity (BMI 30.0 kg/m2) (PR: 1.74, 95% CI: 1.45-2.10) were strongly 
associated with prevalent vitamin D deficiency (serum 25(OH)D level<50nmol/L). 
Our results further indicate that potentially modifiable lifestyle factors were also 
independently associated with vitamin D status.   
In addition to winter season and high BMI, current smoking also showed  an 
increased PR (1.41, 95% CI: 1.21-1.65). Whereas daily intake of cod liver oil (PR: 
0.60, 95% CI: 0.41-0.77), increased physical activity (PR: 0.80, 95% CI: 0.68-0.95) 
and more frequent alcohol consumption (PR: 0.76, 95% CI: 0.60-0.95) were 
associated with a reduced PR.  Similar results were found when serum 25(OH)D level 
<75nmol/L was used as the cut-point (data not presented).   
Approximately 4% of study participants (n=107) had very low serum 25(OH)D 
levels (<25nmol/L) ranging from 10 to 25 nmol/L (figure 2). The median serum 
25(OH)D level in this sub-group was 21 nmol/L. A comparison between participants 
with very low serum 25(OH)D level (<25 nmol/L)and those with serum 25(OH)D 
levels 25 nmol/L showed that the group with very low serum 25(OH)D levels were 
younger, had lower socio-economic status, higher BMI, were less physically active, 
were less likely to take cod liver oil, and had a greater proportion of current smokers. 
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The <25nmol/L group also consumed alcohol fewer times per month, and had a higher 
proportion of blood samples collected during the winter season (table 1). When serum 
25(OH)D level <25nmol/L was used as the cut-point, winter season, high BMI and 
current smoking showed an increased PR, although the confidence intervals were 
much wider compared to data obtained with the <50nmol/L cut-point (table 1). Daily 
intake of cod liver oil, increased physical activity and more frequent alcohol 
consumption were still associated with reduced PR. Although the socio-economic 
(SES) variables remained statistically non-significant, increasing age demonstrated a 
reduced PR in the <25nmol/L group compared to the 25nmol/L group.  
 
 
Figure 2 Unadjusted frequency distribution of study  participants with serum 
25(OH)D<25nmol/L 
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Table 1 Baseline characteristics and adjusted prevalence ratio with 95% confidence intervals for 
serum 25(OH)D level <25nmol/L, in a random sample of adults, the HUNT Study, 1995-1997
 
<25nmol/L  
n=107 
ш25nmol/L 
 n=2,398 p-value
¶ Adjusted PR 95% CI 
Age, years   0.03   
    19-29 25 (23) 353 (15)  1.00 Reference 
    30-39 37 (35) 714 (30)  0.72 0.43, 1.21 
    40-49 33 (31) 951 (40)  0.49 0.28, 0.85 
    50-55 12 (11) 380 (16)  0.44 0.21, 0.91 
Sex   0.62   
    Female 62 (58) 1322 (55)  1.00 Reference 
    Male 45 (42) 1076 (45)  1.02 0.68, 1.53 
Education years   0.05   
    <10 21 (20) 468 (20)  1.00 Reference 
    10-12 67 (63) 1280 (53)  1.07 0.63, 1.81 
    ш13 17 (16) 630 (26)  0.82 0.42, 1.62 
    Unknown 2 (1) 20 (1)    
Social benefit recipient   0.01   
    No 60 (56) 1548 (65)  1.00 Reference 
    Yes 32 (30) 434 (18)  1.36 0.86, 2.15 
    Unknown 15 (14) 416 (17)    
Economic difficulties    0.01   
    No 53 (50) 1430 (60)  1.00 Reference 
    Yes 42 (39) 664 (28)  1.12 0.73, 1.73 
    Unknown 12 (11) 304 (12)    
Season#   <0.001   
    Summer 2 (1) 305 (13)  1.00 Reference 
    Autumn 12 (11) 792 (33)  2.24 0.50, 10.0 
    Winter 67 (63) 688 (29)  12.67 3.10, 51.9 
    Spring 26 (24) 613 (26)  6.43 1.52, 27.2 
Body mass index kg.m-2   0.001   
    <25.0 36 (34) 1068 (45)  1.00 Reference 
    25.0-29.9 45 (42) 1049 (44)  1.44 0.92, 2.26 
    ш30.0 26 (24) 274 (11)  2.54 1.51, 4.26 
    Unknown  7 (0.3))    
Cod liver oil intake   0.004   
    No  74 (69) 1459 (61)  1.00 Reference 
    Yes 5 (4) 336 (14)  0.37 0.15, 0.92 
    Unknown 28 (27) 603 (25)    
Physical activity h.week   0.01   
    <1 40 (37) 532 (22)  1.00 Reference 
    1-2 35 (34) 827 (35)  0.67 0.42, 1.06 
    ш3 28 (26) 745 (31)  0.72 0.44, 1.19 
    Unknown 4 (3) 294 (12)    
Smoking status   <0.001   
    Never 35 (34) 996 (42)  1.00 Reference 
    Current 49 (46) 646 (27)  1.96 1.24, 3.11 
    Former 18 (16) 620 (26)  0.84 0.47, 1.50 
    Unknown 5 (4) 136 (6)    
Alcohol consumption,  
times per month   
<0.001   
    Abstain or ч1 49 (46) 636 (27)  1.00 Reference 
    1-4 45 (42) 1342 (56)  0.43 0.29, 0.66 
     ш5 11 (10) 333 (14)  0.56 0.28, 1.12 
     Unknown 2 (1) 87 (4)                
Data are presented as n (%), unless otherwise stated. 25(OH)D: 25-hydroxyvitamin D; PR: prevalence ratio; CI: 
confidence interval. # Season: summer, June-August; autumn, September-November; winter, December-February; 
spring, March-May. ¶ Fischer’s exact test performed to analyze the difference between <25nmol/L group and 
ш25nmol/L group (missing excluded).    
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4.2 Serum 25-hydroxyvitamin D levels and lung function in adults with 
asthma 
 
Using data from the HUNT Study, we conducted a cross-sectional analysis to 
assess the association between serum 25(OH)D level and lung function in a sample of 
Norwegian adults with asthma (n=898). We also examined possible interactions by sex 
and allergy status.  
A comparison between participants in the final analysis group (n=760) and those 
excluded due to missing information on either exposure or outcome (n=138) showed 
that the analysis group had higher serum 25(OH)D levels, a higher proportion of never 
smokers, were less likely to report regular use of ICS, and had better LF.  
The overall prevalence of vitamin D deficiency (serum 25(OH) D level 
<50nmol/L) in this adult asthma cohort was 44%, which was slightly higher than the 
prevalence of vitamin D deficiency (40%) in the general HUNT population[157].  
The associations between serum 25(OH)D level and LF measures seemed to be 
modified by sex and allergic rhinitis (p<0.03 for 3-way interaction term). In summary, 
serum 25(OH)D level <50 nmol/L was not associated with lower LF in asthmatic 
women with or without allergic rhinitis, or in asthmatic men with allergic rhinitis. 
However, in men with asthma but without allergic rhinitis, serum 25(OH)D level <50 
nmol/L was significantly associated with a much lower FEV1/FVC ratio in comparison 
with the serum 25(OH)D level 50nmol/L group (ȕ= -8.60%;  95% CI: -16.95%        
to -0.25%).  
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When participants with self-reported COPD, chronic bronchitis or emphysema 
were excluded (women: n=40; men: n=43), the association between serum 25(OH)D 
level and LF measures in women with asthma and with or without allergic rhinitis 
remained null. The association between serum 25(OH)D level and FEV1/FVC ratio in 
men with asthma but without allergic rhinitis, remained  (ȕ= -6.98; 95% CI: -12.88    
to -1.06).  
In a further sensitivity analysis we examined how dosage of ICS would 
influence our results. Information on dosage of ICS was obtained from the following 
question, “What is the average daily dosage of ICS that you used last week? (dosage + 
number of inhalations).” The difference in ICS dosage per day between women and 
men was not statistically significant (p=0.237). When dosage of ICS per day was 
included as a covariate in the final adjusted models, we found no change in point 
estimates or confidence intervals (data not presented). Finally, we also obtained 
similar analytical results after multiple imputations of missing data on allergic rhinitis 
and other covariates were performed in adjusted models (data not presented). 
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4.3 Serum 25-hydroxyvitamin D level, smoking and lung function 
changes in adults 
 
Using data from the HUNT Study, we studied the cross-sectional (n=1293) and 
prospective (n=922) interrelationship of serum 25(OH)D, smoking and LF or LF 
changes in a random sample of Norwegian adults.  
At baseline, 40% of adults in this study had serum 25(OH)D level<50nmol/L 
which was consistent with the prevalence of vitamin D deficiency found in Paper 
I[158]. Overall, serum 25(OH)D level<50nmol/L showed worse LF, and increased 
odds for development of LF impairment compared to the 50nmol/L group. These 
associations tended to be stronger amongst ever smokers who showed more decline in 
FEV1/FVC ratio (%) (adjusted  difference: 1.2; 95% CI: 0.1 to 2.2) and greater odds 
for development of LF impairment (adjusted OR for FEV1/FVC<70%: 2.4; 95% CI: 
1.2 to 4.9). Amongst never smokers, no associations between serum 25(OH)D levels 
and LF or LF changes were observed. Cross-sectional and prospective results were 
generally consistent. 
A sensitivity analysis which excluded study participants who self-reported ever 
asthma (n=110), ever COPD (n=10) or both (n=12), gave further confirmation of more 
decline in FEV1/FVC ratio (%) amongst ever smokers with serum 25(OH)D level 
<50nmol/L  (adjusted difference: 1.3; 95% CI: 0.1 to 2.5). Associations amongst never 
smokers remained null. In another sensitivity analysis, we adjusted for pack-years of 
smoking amongst ever smokers and obtained similar analytical results in both cross-
sectional and follow-up studies (data not presented). When LLN was used as a cut-
point to define impaired LF or development of impaired LF, results were weaker but 
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showed a similar trend in comparison to results obtained when FEV1/FVC ratio <70% 
was used as a cut-point (data not presented).  
Table 2 shows a supplementary analysis looking at the difference in baseline 
characteristics between high ( 50nmol/L) versus low (<50nmol/L) serum 25(OH)D 
level amongst never smokers. Never smokers with serum 25(OH)D level  50nmol/L 
were more physically active, had lower BMI, and had a greater proportion of blood 
samples collected during summer months compared to the <50nmol/L group. These 
factors were adjusted in multivariable analysis when the relation of serum 25(OH)D 
levels and LF was assessed in never smokers as well as in ever smokers, and the 
association remained null in never smokers. 
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Table 2 Baseline characteristics of never smokers in a random sample of 
Norwegian adults, the HUNT Study 1995-1997
 
Serum 25(OH)D 
ш50nmol/L (n=340)  
 Serum 25(OH) 
<50nmol/L (n=185) 
p-
value# 
Age, years  39±9.2   38±8.8 0.07 
Sex       0.15 
         Female 195 (57)   94 (51)   
         Male 145 (43)   91 (54)   
25(OH)D (nmol/L)  73±18   38±9 <0.001 
Body mass index kg.m-2  25±4   27±4 <0.001 
Socio-economic status      0.99 
         High 200 (57)   105 (57)   
         Low 109 (31)   57 (31)   
         Unknown 31 (12)   23 (12)   
Season      <0.001 
December-May 129 (38)   141 (76)   
June-November 211 (62)   44 (24)   
Physical activity h.week      0.003 
<1 61 (18)   52 (28)   
ш1 235 (69)   105 (57)   
Unknown 44 (13)   28 (15)   
Ever asthma      0.30 
Yes 304 (89)   171 (92)   
No 35 (35)   14 (8)   
Unknown 1 (0.3)   0   
FEV1 % pred. 
  99±13.5   99±11.7 0.50 
FVC % pred.   100±12.1   100±11.2 0.42 
FEV1/FVC ratio  0.82±0.06   0.82±0.06 0.83 
Data are presented as mean±sd or n(%), unless otherwise stated. HUNT: Nord-Trøndelag Health Study;  
25(OH)D: 25-hydroxyvitamin D; FEV1 % pred.: forced expiratory volume in 1 second percent predicted;  
FVC: forced vital capacity. #: A t-test was performed to analyze the difference between never smokers  
with serum 25(OH)D level 50nmol/L and <50nmol/L for continuous variables and a Chi-squared test 
was applied for categorical variables (missing data were excluded). 
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5 Discussion 
What follows is a presentation of key results from Papers I-III, a discussion of 
strengths and limitations of each study, and a comparison to other papers.  
5.1 Key results 
Our principle findings are hereby summarized: 
¾ Vitamin D deficiency (serum 25(OH)D level<50nmol/L) is relatively high in a 
general Norwegian population (40%), and slightly higher in a Norwegian asthma 
cohort (44%); 
¾ Winter season and high BMI were strongly associated with vitamin D deficiency 
(serum 25(OH)D level<50nmol/L)  in a general Norwegian population. 
¾ Several potentially modifiable lifestyle factors including smoking status, 
physical activity, intake of cod liver oil, and alcohol consumption were also 
independently associated with vitamin D status in a general Norwegian 
population; 
¾ Low serum 25(OH)D level was not associated with airway obstruction in most 
of the adults with asthma, with the exception of men with asthma but without 
allergic rhinitis; and 
¾ Amongst never smokers, we found no significant associations between serum 
25(OH)D levels and lung function or lung function changes in a general 
population of Norwegian adults, however, ever smokers with low serum 
25(OH)D level showed more lung function decline, and increased odds for 
development of lung function impairment. 
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5.2 Methodological considerations 
Methodological considerations related to strengths and weaknesses of the 
epidemiologic studies included in this dissertation (Papers I-III)  will now be discussed 
in turn.  
5.2.1 Random error (imprecision of estimate) 
Random error refers to the likelihood of chance findings and potential variability 
around the data that can be reduced by increasing the sample size[159]. Conversely, 
precision may be defined as lack of random error.  Epidemiologic studies provide 
point estimates which, of themselves, do not express variability in the data. For this 
purpose, confidence intervals (CIs) are used. In Papers I-III we estimated precision 
with 95% CIs, which is to say, if we replicated data collection and analysis n times, 
the true value of the measure would be within the reported CIs, 95% of the time[160]. 
Increased sample size may reduce variance and improve the precision of the estimates. 
As such, studies with large samples have increased precision and narrow CIs, whereas 
studies with small samples have reduced precision and wide CIs.  
In Papers I-III, we had ample sample size to estimate the prevalence of vitamin 
D deficiency (n=2505), the association between serum 25(OH)D level and LF in an 
adult asthma cohort (n=760), as well as the cross-sectional (n=1220) and prospective 
(n=869) associations between serum 25(OH)D level and LF  or LF changes in a 
general population. However, some sub-group analyses in Paper II had fewer within 
stratum observations and wider CIs to indicate reduced precision. These estimates 
should be interpreted with care.  
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5.2.2 Systematic error (lack of internal validity) 
Systematic error is an umbrella term for different types of bias that may be 
present in an epidemiologic study. Unlike random error which is reduced by increasing 
sample size, systematic error (or bias) is an inherent, non-random deviation of results 
that cannot be minimized by increasing sample size[159]. The three categories of 
systematic error are selection bias, information bias and confounding. 
5.2.2.1 Selection bias 
Selection bias is introduced into the study when the study population is 
erroneously selected[160].  This may include selecting the wrong study participants 
such that there is a discernable difference between those who participated in the study 
and those who did not. Other examples of selection bias include loss to follow-up due to 
migration, death, illness or disinterest.   
According to HUNT2[144] and HUNT3[146] non-responder surveys, the main 
reasons for non-participation across age groups reflected in our studies (19-55 years), 
were lack of time, moved away, or inconvenient session. Given the age range of our 
study participants, non-attendants were likely in school, working, or caring for family. 
We may surmise that non-response due to illness is less likely in this age group. As an 
example, no significant difference in the prevalence of asthma was found between 
responders and non-responders in either HUNT2 or HUNT3, thus minimizing selection 
bias in our asthma cohort. However, there were significantly more smokers in the non-
responder group (36%) compared to the responder group (30%) in HUNT2. Following 
this, there were significantly less never smokers in the non-responder group (43%) 
compared to the responder group (46%) in HUNT3. This may have led to an 
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underestimation of current or former smokers, and an overestimation of never smokers 
in our analysis cohorts. Also, men with COPD in HUNT3 had a lower participation rate 
than men without COPD, and women with or without COPD. In Papers II-III, we 
conducted sensitivity analyses that excluded ever COPD patients, so male COPD non-
responders to HUNT3 would not influence our results as they would be otherwise 
excluded from our analyses.  Also, we selected a random sample for serum 25(OH)D 
measurement from the overall cohort, which may compensate for some potential 
selection bias. Some loss to follow up is common in population based studies, 
particularly if persons who are loss to follow up due to migration, illness, death, etc., 
differ in comparison to those who remain in the study. In our Paper III we were able to 
follow-up 70% of study participants from HUNT2 to HUNT3. Strong follow-up  in 
conjunction with non-responder data gives us some confidence that we were able to  
minimize selection bias.  
Missing data from survey non-response is another type of selection bias. For 
Papers I and II, we used the multivariate imputation by chained equations (MICE) 
method to impute fifty datasets of missing data on the covariates with missing 
information and we observed similar results (data not presented) (Section 3.8). 
5.2.2.2 Information bias 
Information bias occurs during data collection and refers to measurement error 
that results in an incorrect estimate of the association between exposure and 
outcome[160]. Inaccurate measurement of exposure, covariate or outcome variables can 
occur. Information bias may further be divided into misclassification bias, detection 
bias, recall and observer bias, and reporting bias.  
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There are two types of misclassification to be aware of in epidemiologic studies, 
namely, non-differential and differential misclassification[159]. If all groups of subjects 
or categories of a variable have equal probability of being misclassified and therefore 
have the same error rate, the misclassification is said to be non-differential. In contrast, 
if the probability of being misclassified differs across groups of study subjects resulting 
in a different error rate in each group to be compared, the misclassification is said to be 
differential. Erroneous information, whether non-differentially or differentially 
misclassified, can give a biased estimate either toward or away from the null.  
Detection bias, particularly systematic differences in measurement of outcome 
variables, is important to consider in cohort studies[160]. Valid and reliable outcome 
measures will greatly reduce detection bias. Recall and observer bias are similar in that 
the participant or interviewer may lack impartiality and may be guided by some form of 
prior knowledge that may lead to a biased response. Finally, reporting bias often 
happens when the participant reports incorrect information, if for example the 
inaccurate response is deemed more socially desirable than the accurate response. 
Furthermore, responses given by a proxy may prove to be a source of inaccurate 
information.  Many forms of information bias can be minimized by participant or 
interviewer blinding, or by implementing a standardized protocol[160].  
By nature of the HUNT study design, some information bias within 
questionnaire data might be expected. For example, questionnaire 1 in both HUNT2 and 
HUNT3 surveys were mailed to each potential participant who then completed the 
questionnaire by self or by proxy which may contribute to reporting bias. However, 
participants then attended a clinical examination where trained health professionals 
48 
 
received the questionnaire and provided additional support if needed. This follow-up 
may limit potential erroneous or missing information. Regarding our asthma cohort in 
Paper II, participants  with asthma may forget a childhood diagnosis of asthma, or may 
have been given a diagnosis like recurrent bronchitis instead of asthma[150]. Participant 
results from clinical exam were shared with the family physician[142]. Participant 
awareness around the possibility of validated responses by family physician may have 
reduced reporting bias.  
The serum 25(OH)D levels and lung function measures used in our studies were 
obtained by trained professionals using standardized protocols and quality controlled 
methods (Section 3.5-3.6). However, spirometry is dependent on technique and 
standardization may be difficult to adhere to in population based studies. Important 
failures may include too low initial flow or too short expiration time, however FEV1 is a 
robust parameter that seems to have high validity[150].  In addition, some covariates 
may have been misclassified due to self-report. For example, a skin prick test or 
measurement of allergen-specific IgE would give more accurate information on allergy 
status[63]. Also, assessment of cotinine levels in biological fluid may provided a more 
accurate categorization of smoking status[161]. In future, studies using HUNT biobank 
data could conduct validation studies  in sub-samples of the survey population to 
determine self-report accuracy.  
5.2.2.3 Confounding 
Confounding is a critical concept in epidemiology, particularly in observational 
studies when it is rarely possible for individuals to be randomly assigned[162].  Study 
participants who share a particular risk, vitamin D deficiency for example, also have 
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other characteristics in common that influence their risk of disease. In experimental 
studies, randomization ensures that each treatment group has a similar risk of the 
outcome at baseline. In this context, the difference between treatment groups is said to 
be causal[162]. However, observational studies are limited in that one cannot be sure if 
subjects in different exposure groups are similar with respect to all other factors.   
Confounding can be defined as a mixture of the effect of an exposure with effects of 
other factors[159].  Confounding may lead to an underestimation, overestimation, or a 
change in the direction of the estimate[159].  
 In order for a variable to be a confounder it must be independently associated 
with both the exposure and the outcome, must not be along the causal pathway between 
the exposure and outcome, and must not be a consequence of the outcome[159, 162]. 
There is no statistical test for confounding[162]. One’s ability to accurately identify a 
confounder is based on expert and/or priori knowledge from the literature.  
The HUNT studies constitute a comprehensive database of clinical, lifestyle and 
environmental information collected over 25 years. Using data from HUNT2 and 
HUNT3, we were able to control for a wide range of possible confounding factors in 
our studies (Sections 3.8 and 3.9). Literature on serum 25(OH)D levels and lung 
function in adults is growing, but still sparse. Information on potential confounders of 
this association is also lacking.. We can therefore not discount the possibility of 
residual or unmeasured confounding in our studies. For example, in Paper I we lacked 
full information on alcohol consumption including quantity, frequency and type of 
alcohol consumed. Therefore, the association between increased alcohol consumption 
and lower prevalence ratio for vitamin D deficiency may be subject to residual 
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confounding.  For Paper II we had information on cod liver oil intake, however, other 
dietary intakes and nutrition may be a common cause of both vitamin D deficiency and 
asthma onset or severity[163].  Regarding adverse lung function changes in Paper III, 
we did not control for possible workplace exposure which may or may not be 
associated with vitamin D status. However, for unknown confounding to substantially 
impact our findings, the variable must not be associated with any other variable we 
controlled for in the analyses, and must be strongly associated with both exposure and 
outcome. Future studies on vitamin D status and lung function in adult asthma or adult 
general populations will provide further information concerning confounding.  
5.3 Generalizability (external validity) 
Regarding the generalization of epidemiologic results, this section is not 
concerned with statistical representativeness based on sampling from a source 
population as previously discussed under selection bias (Section 5.1.2.1). Rather, in this 
section we consider generalization of epidemiologic results within the context of 
biological representativeness of scientific findings[159]. For example, our study results 
from a general adult population (aged 19-55) in Norway cannot be considered 
biologically comparable to infants, children, the elderly or diseased populations. 
Likewise, our findings within the adult asthma cohort cannot be considered biologically 
comparable to general or healthy populations, or COPD patients. Furthermore, the 
HUNT study population is mostly Caucasian (97%)[141] which may reduce the 
generalizability of our research findings to more ethnically diverse populations. 
However, since the HUNT study represents a population based cohort, the prevalence 
and incidence of diseases and determinants of disease are comparable to those of other 
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northern European countries[33]. Finally, our analysis cohorts can be considered 
representative of ethnic Norwegian populations which provides a platform for 
biomarker-based research that may be undertaken in the future[33]. 
5.4 Comparison with other studies 
5.4.1 Prevalence of vitamin D deficiency 
In our study, the prevalence of vitamin D deficiency (serum 25(OH)D level <50 
nmol/L) was high in a general population of Norwegian adults (40%) and higher in an 
asthma cohort of Norwegian adults (44%). Comparisons on the prevalence of vitamin 
D deficiency are difficult due to the lack of general consensus regarding cut-points, 
and varying use of terminology to define these cut-points[24, 27]. For example, a  
serum 25(OH)D level between 30-50nmol/L has been defined as “inadequate”[24], 
and levels below 50nmol/L have been defined as “deficient”[27], or “insufficient”[29]. 
The widely recommended cut-points to define vitamin D deficiency and insufficiency 
are serum 25(OH)D levels <50nmol/L, and <75nmo/L, respectively[17].  In this paper, 
we considered serum 25(OH)D level <50nmol/L as  deficient. 
The mean level of serum 25(OH)D in Paper I (59 nmol/L) was comparable to 
that from another population based study of adults aged 25-84 years conducted in 
Northern Norway (55 nmol/L)[164]. However, the prevalence of vitamin D deficiency 
in our study tended to be higher than was found in some other studies. For example, 
the prevalence of vitamin D deficiency between May and January was 14% in a cross-
sectional study of healthy Norwegian adults living in Oslo[42], compared to 34% of 
participants in our study whose blood samples were collected during the same time. 
The Oslo study selected a random sample of participants aged 45, 60, and 75. Older 
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participants may be more likely to supplement with vitamin D[51]. A recent Canadian 
study reported a 20% overall prevalence of vitamin D deficiency in adults aged over 
35, but a larger proportion of the Canadian study participants reported regular intake 
of vitamin D through supplementation or fortified food intake[165]. In contrast, an 
earlier study from our research group estimated that only 18% of HUNT participants 
took cod liver oil regularly[51]. The blood sample collection in our study (1995-97) 
was 10 years previous to the Canadian study (2005-07). However, results from a 
recent prospective study in the United States suggested high intra-individual 
reproducibility[166]. This may indicate that the two studies can be compared despite 
serum 25(OH)D levels being measured at different time points. On the other side, this 
intra-individual reproducibility may be lacking in high latitude populations undergoing 
a cultural shift resulting in a change away from traditional practices, including 
traditional diet. A new study of Arctic Inuit in Greenland showed a marked decline in 
serum 25(OH)D levels  over 13 years, with a  decrease in serum 25(OH)D 
concentrations ranging from 33% to 58%, depending on age and sex[43]. The authors 
suggest that a change away from traditional diet may be the main reason for this 
dramatic shift in vitamin D status. Despite documented belief that higher vitamin D 
status in Norway is due to a traditional diet[14],  82% of HUNT participants do not 
take cod liver oil regularly[51]. Like the Greenlandic population, departure from a 
traditional Norwegian diet may have influenced the overall vitamin D status in our 
study population.    
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5.4.2 Factors associated with vitamin D deficiency 
We found that winter season and high BMI were the two strongest factors 
associated with vitamin D deficiency in our large random sample of a general 
Norwegian population. Our results also indicate that potentially modifiable lifestyle 
factors including intake of cod liver oil, physical activity, smoking and alcohol 
consumption were independently associated with vitamin D status. These associations 
persisted when we used serum 25(OH)D level <75nmol/L and <25nmol/L as 
additional cut-points. 
Winter season was the strongest factor associated with vitamin D deficiency in 
our study, as found in many other studies[15, 42, 43, 62, 164]. This finding is not at 
all surprising considering the high latitude of Nord-Trøndelag county (64° North) and 
the lack of UVB radiation available at this latitude during winter season[1, 38]. High 
BMI was the second strongest factor associated with low vitamin D status in our 
study. Due to the cross-sectional design of our study we cannot infer causality, but the 
literature suggests a potentially  harmful cycle between high BMI and low 25(OH)D 
levels. Vitamin D may be stored in adipose tissue due to its  fat soluble character. In 
this way, high BMI leads to low vitamin D status[52, 167]. However, low vitamin D 
may lead to obesity due to the promotion of lipogenesis in adipocyte tissue[61, 147].  
A recent study that used genetic markers as an instrumental variable to explore the 
causality and direction of the relationship between circulating 25(OH)D levels and 
BMI, suggested that higher BMI led to lower 25(OH)D levels, but the reverse was not 
true[54]. Further research is warranted to clarify the causal relationship between 
vitamin D status and BMI. 
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As expected, regular intake of cod liver oil was associated with higher serum 
25(OH)D levels as shown in other studies[41, 45, 46]. Increased awareness around the 
benefits of taking cod liver oil, especially during winter months, could be an 
important public health message in Norway considering the long tradition of cod liver 
oil intake in the country, and the lower than expected proportion of HUNT 
participants who reported taking cod liver oil regularly. 
Increased hours of light physical activity was associated with higher serum 
25(OH)D levels, but physical activity may be a proxy measure for sun exposure due 
to increased leisure time spent outdoors, as found in other studies[165, 168, 169].  
Still, some evidence suggests that increased physical activity may be a factor 
associated with vitamin D status independent of the effect of sun exposure[53]. Thus, 
the role of physical activity in modulating circulating 25(OH)D levels, independent of 
sun exposure, is a potential area for future research.  
In our study, current smoking was associated with an increased prevalence ratio 
(PR) for vitamin D deficiency. Previous European studies have shown a positive 
association between smoking and vitamin D deficiency [58, 59, 170, 171]. One study 
in northern Norway found higher serum 25(OH)D levels in smokers, which the 
authors believed to be most likely due to measurement error and smokers were 
therefore excluded from further analysis[164]. Other studies found no association 
between smoking and vitamin D status [53, 60]. Cigarette smoke causes inflammation 
[121], and vitamin D may modulate an immune response triggered by smoking-
induced inflammation[122]. This process may reduce the bioavailable concentrations 
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of serum 25(OH)D in smokers, resulting in lower levels of serum 25(OH)D available 
for measurement.   
Interestingly, we found that more regular alcohol consumption was associated 
with higher levels of serum 25(OH)D. Since the publication of Paper I, at least two 
additional studies report a similar association in support of our finding[43, 172]. 
Although the mechanism for how alcohol consumption might affect serum 25(OH)D 
level is unclear, alcohol induced impairment of  parathyroid hormone (PTH)  secretion 
may be one reason[61].  PTH secretion increases the enzyme responsible for 
converting serum 25(OH)D to the biologically active form[61]. If this process is 
impaired, unconverted serum 25(OH)D may lead to higher serum 25(OH)D levels in 
the circulation when measured. However, this mechanistic theory is highly speculative 
and the association between serum 25(OH)D levels and alcohol consumption should 
be further evaluated using well defined variables including quantity, frequency and 
type of alcohol consumption. 
None of the socio-demographic markers were substantially associated with 
vitamin D deficiency in this Norwegian population which seems plausible given the 
socio-political structure of Norway as a social democratic welfare state[173, 174]. Our 
results were consistent with findings from two other Norwegian studies in which no 
difference between women and men were found[42, 164]. Still, marginalized socio-
demographic status has been identified as a risk factor for low vitamin D status in 
other populations[11, 171, 172]. Findings by socio-demographics in other studies may 
be related to more pronounced strata by social class in countries with socio-political 
structures that differ from Norway. Reduced health literacy, particularly in younger 
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age groups, may also explain some risk for vitamin D deficiency in these populations. 
Moreover, reduced health literacy in the youngest ages of our HUNT population, may 
partly explain why a significant proportion of younger people in our study had serum 
25(OH)D level<25nmol/L, and why increasing age was associated with a reduced 
prevalence ratio in this <25nmol/L group, but not in our overall cohort. The potential 
association between socio-demographics and vitamin D deficiency in our study may 
also be mediated by lifestyle factors. 
5.4.3 Serum 25(OH) D level and airway obstruction in adult asthma 
In our study, low serum 25(OH)D level was not associated with airway 
obstruction in most adults with asthma, with the exception of a sub-group of men. In 
men with asthma but without allergic rhinitis, low serum 25(OH)D level was 
associated with a considerably reduced FEV1/FVC ratio. Multiple imputation of 
missing data and a sensitivity analysis that excluded persons who reported ever COPD 
status gave similar results.   
Although several studies have observed an association between serum 25(OH)D 
level and lung function in a general population of adults[104-106, 108, 137, 175], or in 
children with asthma[100, 176],  prior studies in adult asthma cohorts are scarce. A 
small clinical trial of 54 US adults with persistent asthma reported an association 
between reduced continuous serum 25(OH)D with impaired FEV1 and increased 
AHR[110].  A Chinese study of 435 adults with asthma found a significant association 
between vitamin D deficiency (<50 nmol/L) and low values for FEV1/FVC ratio and 
FEV1[111]. However, this study did not report sex-specific results. 
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Regarding a sex difference, a most recent report in children with asthma 
provided consistent results of an association between low plasma 25(OH)D levels with  
low FEV1/FVC ratio and  FEV1 in boys[177]. Two studies in general adult populations 
provide additional support to our sex specific finding in adults with asthma[106, 108]. 
A  study of 3359 Canadian adults observed an association between vitamin D 
deficiency (<50 nmol/L) and worse  lung function (FEV1 and FVC, but not FEV1/FVC 
ratio) in  men [108]. In the Longitudinal Aging Study Amsterdam, a strong association 
between serum 25(OH)D and peak expiratory flow rate (PEFR) was observed in older 
men but not in older women[106]. Our observation in asthmatic men but not women 
does not seem to be explained by type 2 error in women (false negative finding) due to 
a comparable number of women (n=446) and men (n=314) in our analyses. Asthmatic 
men in our study had lower lung function compared with asthmatic women 
(FEV1/FVC ratio (%): men, 75±0.5; women, 78±0.4). Women with asthma in our 
study were more likely than men with asthma to report use of asthma medication, 
which may indicate greater compliance with recommended treatment for asthma and 
thus better lung function. However, a previous Canadian study indicated that sex may 
modify the association between asthma and lung function, i.e. the association of 
asthma with lower lung function was stronger in men than in women[178]. Even 
though a sex-specific finding seems plausible, further investigation and confirmation 
regarding the association between serum 25(OH)D and lung function in adult asthma 
is needed.  
Our finding of an association between low serum 25(OH)D level and reduced 
FEV1/FVC ratio in men with asthma but without allergic rhinitis is consistent with an 
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earlier study from our research group in which an association between low serum 
25(OH)D and incident asthma was demonstrated only among men with no allergy 
status[91]. Furthermore, an association between low serum 25(OH)D levels and ever 
asthma in non-atopic subjects has been reported [90].  A recent genome-wide 
association study reported an association between TH1 non-allergic pathway genes and 
lung function in asthmatic subjects[179], while lower serum 25(OH)D3 levels have 
also been associated with thicker airway smooth muscle (ASM) mass in children with 
severe asthma [99].  The modulating effect of serum 25(OH)D on the contraction, 
inflammation and remodeling of ASM function[79]  is one possible mechanism for 
airway obstruction in asthma subjects. In light of this evidence, we suggest that low 
serum 25(OH)D levels may be associated with airway obstruction  and may influence 
the development of asthma, as well as asthma severity and control  via the non-allergic 
pathway. 
5.4.4 Serum 25(OH)D level, smoking and lung function changes in adults 
 
In this general population of Norwegian adults, serum 25(OH)D levels 
<50nmol/L were associated with worse LF and increased odds for development of  LF 
impairment compared to the 50 nmol/L group. These associations seemed stronger in 
the ever smoker group, amongst whom more LF decline in FEV1/FVC ratio was also 
observed. Associations in never smokers were null.  Cross-sectional and prospective 
results were consistent.  
Several cross-sectional studies have reported an association between low vitamin 
D status and lower lung function in general adult populations[104, 108, 175]. To date, 
three prospective studies on vitamin D status and lung function changes in general 
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adult populations have been published[105, 114, 115], but findings from these studies 
lack consistency. Our findings were somewhat supported by Afzal et. al[115] who 
found a prospective association between smokers with lowest plasma 25(OH)D 
quintile and more decline in LF in comparison to smokers with highest plasma 
25(OH)D quintile (difference in decline in FEV1 % pred./year: 0.47, 95% CI: 0.38-
0.56). Afzal et al. also report an association between low serum 25(OH)D levels  and 
increased risk for development of COPD[115].These results were replicated in two 
independent samples. However, these  findings have recently been criticized by 
Young and Hopkins[138]. First, Young and Hopkins suggest a threshold effect for the 
association between vitamin D status and lung function. Second, they cite concern 
with the overall estimates for an association between vitamin D status and FEV1 % 
pred. which were consistently mirrored by a corresponding association between 
vitamin D status and FVC % pred., while no effect was observed for FEV1/FVC 
ratio[138, 139]. In response to this critique, Afzal et. al state that the observed 
significant interaction suggests a stronger association between vitamin D status and 
FEV1% pred. in individuals with airway obstruction[139]. Young and Hopkins 
theorize further that the reduction in lung function found by Afzal et. al, could be 
explained by the confounding or mediating effects of frailty in older persons or 
systemic inflammation, both of which correlate with low vitamin D status (serum 
25(OH)D level <50 nmol/L)[138] . These critiques also have bearing on our results. 
Although it is true that increased systemic inflammation has been linked to greater LF 
decline[129], it is also true that cigarette smoke can directly induce systemic 
inflammation[128]. Our analysis was conducted overall, and separately in ever and 
never smokers. To some extent, we thereby controlled for systemic inflammation 
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caused by smoking. Furthermore, our study population consisted of relatively young 
participants aged 19-55 years, thus reducing the likelihood of confounding due to 
frailty.  Finally, we observed a change in FEV1 % pred. and FEV1/FVC ratio <70%, 
which is the recommended cut-point to determine possible COPD[102], but we found 
no significant change in FVC % pred. However, due to the observational nature of our 
study and due to the fact that our study lacked post bronchodilator spirometry for 
COPD diagnosis, causal statements regarding the interrelationship between serum 
25(OH)D level, smoking and COPD are not possible. 
Our results are also consistent with those of a longitudinal cohort of elderly men 
in the US[105] that suggested a serum 25(OH)D level 50nmol/L may protect against 
lower LF and more rapid LF decline in smokers[105]. However, this US study 
included male only participants aged 21 to 80 years, some of whom had chronic 
conditions. Thus, a generalization of these findings to our general adult population 
may not be possible.   
In contrast to our findings and to those of Afzal et. al[115], another prospective 
Danish study by Thuesen et. al[114] found higher levels of serum 25(OH)D to be 
significantly associated with adverse LF changes. Given that both Danish studies had 
large sample sizes derived from a general adult population in Copenhagen, the 
prospective results in opposite directions are not easily explained. Method-related 
differences based on different assays used for measurement of serum 25(OH)D levels 
may be one explanation. Like our study, Afzal et. al[115] used DiaSorin 
radioimmunoassay for serum 25(OH)D measurement, whilst Thuesen et. al[114] used 
liquid chromatography for serum 25(OH)D measurement. It has been suggested that 
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results given by different assay methods lack comparability, and that results from 
liquid chromatography are relatively high compared to those of DiaSorin 
radioimmunoassay[116].  
Smoking is the main risk factor for COPD[119], and COPD is rarely 
reversible[180]. By using a standard cut-point to define airflow limitation (FEV1/FVC 
ratio <70%)[102], our finding amongst ever smokers suggests that lower serum 
25(OH)D levels may indicate a potential risk for future development of COPD. As 
mentioned above, at least one prospective study reported an association between 
lowest plasma 25(OH)D quintile and risk of COPD[115], although the accuracy of 
this finding is being debated[138, 139]. A small randomized trial of participants with 
moderate to very severe COPD and a history of recent exacerbations (n=182), 
reported a reduction in COPD exacerbations when high doses of vitamin D 
supplementation (100,000 IU every 4 weeks for 1 year) were given to trial participants 
with baseline serum 25(OH)D levels <25nmol/L[135]. To be noted this post hoc 
finding was only true for the <25nmol/L group, where no reduction in COPD 
exacerbations was found in the overall study population[135]. Moreover, a 
longitudinal study of COPD patients found no prospective association between 
baseline vitamin D status and rate of LF decline in slow versus rapid decliners[136]. 
Further evidence to fully elucidate the association between serum 25(OH)D levels, 
smoking and COPD, is needed. It is also important to gain an understanding on the 
relevance and efficacy of vitamin D supplementation as an intervention strategy to 
mitigate the risk of disease onset amongst smokers, or to reduce exacerbations 
amongst COPD patients. 
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6 Conclusions and future perspectives 
Findings from this dissertation are derived from three original epidemiologic 
studies based on vitamin D status and serum 25(OH)D level as the exposure of interest, 
and lung function or lung function changes as outcomes of interest. Asthma, allergic 
rhinitis, smoking status, and COPD were additional key study elements.   
Data from Paper I suggests a high prevalence of vitamin D deficiency (serum 
25(OH)D level <50 nmol/L) in a Norwegian adult population. Besides season and BMI, 
several potentially modifiable lifestyle factors were independently association with 
vitamin D status. Regular intake of cod liver oil is a potential area for increased public 
health messaging in Norway.  
In Paper II, we found no association between serum 25(OH)D level and lung 
function in most adults with asthma, with the exception of men with asthma but without 
allergic rhinitis. The observed interactions by sex and allergy status warrant further 
investigation and replication. A well-designed prospective study on serum 25(OH)D 
and lung function changes in an asthma cohort are called for.  
In Paper III, data amongst never smokers showed no clear associations between 
serum 25(OH)D levels and lung function (cross-sectionally) or lung function changes 
(prospectively).  However, lower serum 25(OH)D levels seemed to be associated with 
more lung function decline and increased odds for development of lung function 
impairment amongst ever smokers. These findings suggest that higher 25(OH)D 
concentrations may be partially protective against future development of COPD in 
smokers.   
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 If confirmed by other studies, these results suggest that vitamin D 
supplementation may be a potentially cost effective, safe and straightforward means of 
asthma control and COPD prevention. Continued research on serum 25(OH)D levels 
and lung function changes in well designed prospective and intervention studies are 
called for. By measuring serum 25(OH)D levels in a large sample of Norwegian 
participants from the HUNT2 Study, our research group has built up serum 25(OH)D 
samples which can benefit future vitamin D research,  including biomarker studies.  
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